Verrica Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Verrica Pharmaceuticals' es Ted White , nombrado en Dec 2017, tiene una permanencia de 6.33 años. compensación anual total es $3.50M, compuesta por 17.1% salario y 82.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.22% de las acciones de la empresa, por valor de €602.07K. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 5.9 años, respectivamente.

Información clave

Ted White

Chief Executive Officer (CEO)

US$3.5m

Compensación total

Porcentaje del salario del CEO	17.1%
Permanencia del CEO	6.4yrs
Participación del CEO	0.4%
Permanencia media de la dirección	4.6yrs
Promedio de permanencia en la Junta Directiva	6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ted White en comparación con los beneficios de Verrica Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$4m	US$601k	-US$67m
Sep 30 2023	n/a	n/a	-US$48m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$23m
Dec 31 2022	US$2m	US$572k	-US$24m
Sep 30 2022	n/a	n/a	-US$28m
Jun 30 2022	n/a	n/a	-US$41m
Mar 31 2022	n/a	n/a	-US$43m
Dec 31 2021	US$2m	US$550k	-US$35m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$36m
Mar 31 2021	n/a	n/a	-US$34m
Dec 31 2020	US$2m	US$485k	-US$43m
Sep 30 2020	n/a	n/a	-US$37m
Jun 30 2020	n/a	n/a	-US$33m
Mar 31 2020	n/a	n/a	-US$31m
Dec 31 2019	US$1m	US$433k	-US$28m
Sep 30 2019	n/a	n/a	-US$28m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$26m
Dec 31 2018	US$5m	US$400k	-US$21m
Sep 30 2018	n/a	n/a	-US$20m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$24k	US$24k	-US$10m

Compensación vs. Mercado: La compensación total de Ted($USD3.50M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD705.27K).

Compensación vs. Ingresos: La compensación de Ted ha aumentado mientras la empresa no es rentable.

CEO

Ted White (58 yo)

6.4yrs

Permanencia

US$3,504,647

Compensación

Mr. Ted White has been the President and Chief Executive Officer at Verrica Pharmaceuticals Inc. since December 2017 and has been its Director since May 2018. Mr. White served as the President and General...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ted White	President	6.4yrs	US$3.50m	0.40% $ 1.3m
Christopher Hayes	Chief Legal Officer	5.7yrs	US$2.56m	0.29% $ 915.0k
Joe Bonaccorso	Chief Commercial Officer	6.3yrs	US$2.10m	0.22% $ 686.1k
P. Terence Kohler	Chief Financial Officer	2.8yrs	sin datos	0.081% $ 255.6k
Gary Goldenberg	Chief Medical Officer	3.8yrs	US$989.18k	0.10% $ 315.6k
Eugene Scavola	Executive Vice President of Technical Operations	4.6yrs	sin datos	sin datos
Bradley Catalone	Head of Drug Development	3.8yrs	sin datos	sin datos

4.6yrs

Permanencia media

58.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1NE se considera experimentado (4.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ted White	President	6yrs	US$3.50m	0.40% $ 1.3m
Mark Prygocki	Independent Director	6yrs	US$119.19k	0% $ 0
Mark Lebwohl	Member of Scientific Advisory Board	no data	sin datos	sin datos
Lawrence F. Eichenfield	Independent Director	3.8yrs	US$119.19k	0% $ 0
Sean Stalfort	Director	8.4yrs	sin datos	1.09% $ 3.4m
Paul Manning	Chairman of the Board	8.4yrs	sin datos	36.15% $ 113.9m
Craig Ballaron	Independent Director	4.9yrs	US$119.19k	0.024% $ 74.2k
Steven Cohen	Member of Scientific Advisory Board	no data	sin datos	sin datos
Elaine Siegfried	Member of Scientific Advisory Board	no data	sin datos	sin datos
Anthony Mancini	Member of Scientific Advisory Board	no data	sin datos	sin datos
Janice Pelletier	Member of Scientific Advisory Board	no data	sin datos	sin datos
Robert Greenberg	Member of Scientific Advisory Board	no data	sin datos	sin datos

6.0yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de 1NE se considera experimentada (5.9 años de antigüedad promedio).

Verrica Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024

Chief Financial Officer recently sold €76k worth of stock

Insufficient new directors

Chairman of the Board recently bought €907k worth of stock

Director recently bought €488k worth of stock

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 09, 2022

Recent updates

Verrica Pharmaceuticals Inc. to Report Q1, 2024 Results on May 13, 2024

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

Forecast to breakeven in 2026

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$1.48 loss per share (vs US$0.72 loss in FY 2022)

Verrica Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 29, 2024

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services

Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™? for the Treatment of Common Warts

Forecast to breakeven in 2026

Chief Financial Officer recently sold €76k worth of stock

New minor risk - Profitability

New minor risk - Profitability

Verrica Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Verrica Pharmaceuticals Inc. Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma At the American Academy of Dermatology 2023 Innovation Academy Meeting

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.24 loss per share (vs US$0.37 loss in 2Q 2022)

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association's 2023 Innovation Academy Meeting

Insufficient new directors

Chairman of the Board recently bought €907k worth of stock

New major risk - Share price stability

Verrica Pharmaceuticals Inc. Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

Forecast to breakeven in 2025

No longer forecast to breakeven

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.31 loss in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: US$0.72 loss per share (vs US$1.30 loss in FY 2021)

Forecast to breakeven in 2025

Verrica Pharmaceuticals Inc. Resubmits New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Forecast to breakeven in 2025

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.47 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.43 loss in 2Q 2021)

Jakubowitz Law Reminds Verrica Shareholders of a Lead Plaintiff Deadline of August 5, 2022

Director recently bought €488k worth of stock

Verrica Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $25.2 million.

Verrica Pharmaceuticals Inc.(NasdaqGM:VRCA) dropped from Russell 2000 Growth Index

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc

No longer forecast to breakeven

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 09, 2022

Verrica Pharmaceuticals Inc. Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-In-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

No longer forecast to breakeven

Forecast to breakeven in 2024

Verrica Pharmaceuticals Inc. Announces Acceptance by FDA of NDA Resubmission for VP-102

Chairman of the Board recently bought €415k worth of stock

Verrica Pharmaceuticals Inc. Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Inc. Receives Complete Response Letter from the FDA Identifying Deficiencies At Facility of Contract Manufacturer for Its New Drug Application for Vp-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Inc. Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Inc. Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts

Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP 102 in Patients with Common Warts

JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials

Verrica Pharmaceuticals Inc.(NasdaqGM:VRCA) dropped from Russell Microcap Value Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad